Jasper Therapeutics, Inc. (JSPR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US4718712023
Price
13.68 USD
Market cap
15.17 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–
Jasper Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -83.88 m USD |
| EBIT | -77.54 m USD |
| Net income | -75.80 m USD |
| Diluted EPS – continuing operations | -3.95 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of biologic agents to enhance the outcomes in patients with immunologically-driven disorders. The company is based in Redwood City, California.
More stocks
- Acumen Pharmaceuticals, Inc. (ABOS)
- ASHFORD HOSPITALITY TRUST INC (AHT)
- TRANSUITE.ORG INC. (TRSO)
- SBI Investment KOREA Co. Ltd (019550.KQ)
- Longduoduo Co Ltd (LDDD)
- Allarity Therapeutics, Inc. (ALLR)
- Cytosorbents Corp (CTSO)
- Pluri Inc. (PLUR)
- Bridger Aerospace Group Holdings, Inc. (BAER)
- Investcorp Credit Management BDC, Inc. (ICMB)
- Security Midwest Bancorp, Inc. (SBMW)
- American Strategic Investment Co. (NYC)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.